H
Hans C. Lee
Researcher at University of Texas MD Anderson Cancer Center
Publications - 157
Citations - 2334
Hans C. Lee is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 17, co-authored 118 publications receiving 1244 citations.
Papers
More filters
Journal ArticleDOI
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial,Hans C. Lee,Ashraf Badros,Suzanne Trudel,Ajay K. Nooka,Ajai Chari,Al-Ola Abdallah,Natalie S. Callander,Nikoletta Lendvai,Douglas W. Sborov,Attaya Suvannasankha,Katja Weisel,Lionel Karlin,Edward N. Libby,Bertrand Arnulf,Thierry Facon,Cyrille Hulin,K. Martin Kortüm,Paula Rodriguez-Otero,Saad Z. Usmani,Parameswaran Hari,Rachid Baz,Hang Quach,Philippe Moreau,Peter M. Voorhees,Ira Gupta,Axel Hoos,Eric Zhi,January Baron,Trisha Piontek,Eric Lewis,Roxanne C. Jewell,Elisha J. Dettman,Rakesh Popat,Simona Degli Esposti,Joanna Opalinska,Paul G. Richardson,Adam D. Cohen +37 more
TL;DR: Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.
Qing Deng,Guangchun Han,Nahum Puebla-Osorio,Man Chun John Ma,Paolo Strati,Beth Chasen,Enyu Dai,Minghao Dang,Neeraj Jain,Haopeng Yang,Yuanxin Wang,Shaojun Zhang,Ruiping Wang,Runzhe Chen,Jordan Showell,Sreejoyee Ghosh,Sridevi Patchva,Qi Zhang,Ryan Sun,Frederick B. Hagemeister,Luis Fayad,Felipe Samaniego,Hans C. Lee,Loretta J. Nastoupil,Nathan Fowler,R. Eric Davis,Jason R. Westin,Sattva S. Neelapu,Linghua Wang,Michael R. Green +29 more
TL;DR: Heterogeneity in the cellular and molecular features ofCAR T cell infusion products contributes to variation in efficacy and toxicity after axi-cel therapy in LBCL, and that day 7 molecular response might serve as an early predictor of CAR T cell efficacy.
Journal ArticleDOI
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: Safety run-in results of ANDROMEDA
Giovanni Palladini,Efstathios Kastritis,Mathew S. Maurer,Jeffrey A. Zonder,Monique C. Minnema,Ashutosh D. Wechalekar,Arnaud Jaccard,Hans C. Lee,Naresh Bumma,Jonathan L. Kaufman,Eva Medvedova,Tibor Kovacsovics,Michael Rosenzweig,Vaishali Sanchorawala,Xiang Qin,Sandra Y. Vasey,Brendan M. Weiss,Jessica Vermeulen,Giampaolo Merlini,Raymond L. Comenzo +19 more
TL;DR: Daratumumab-CyBorD was well tolerated, with no new safety concerns compared with the intravenous formulation, and demonstrated robust hematologic and organ responses.
Journal ArticleDOI
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Jo Ishizawa,Kensuke Kojima,Kensuke Kojima,Dhruv Chachad,Peter P. Ruvolo,Vivian Ruvolo,Rodrigo Jacamo,Gautam Borthakur,Hong Mu,Zhihong Zeng,Yoko Tabe,Yoko Tabe,Joshua E. Allen,Zhiqiang Wang,Wencai Ma,Hans C. Lee,Robert Z. Orlowski,Dos D. Sarbassov,Philip L. Lorenzi,Xuelin Huang,Sattva S. Neelapu,Timothy J. McDonnell,Roberto N. Miranda,Michael Wang,Hagop M. Kantarjian,Marina Konopleva,R. Eric Davis,Michael Andreeff +27 more
TL;DR: The results suggest that by inducing an atypical ISR and p53-independent apoptosis, ONC201 has clinical potential in hematological malignancies.
Journal ArticleDOI
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Simon J. Harrison,Simon J. Harrison,Monique C. Minnema,Hans C. Lee,Andrew Spencer,Prashant Kapoor,Deepu Madduri,Jeremy T. Larsen,Sikander Ailawadhi,Jonathan L. Kaufman,Marc S. Raab,Parameswaran Hari,Shinsuke Iida,Ravi Vij,Faith E. Davies,Robin Lesley,Vijay V. Upreti,Zhao Yang,Anjali Sharma,Alex C. Minella,Suzanne Lentzsch +20 more
TL;DR: AMG 701, a BiTE® molecule binding BCMA on MM cells and CD3 on T cells, in RR MM was evaluated to evaluate safety and tolerability and estimate a biologically active dose to characterize pharmacokinetics, anti-myeloma activity, and response duration.